Company Overview

Aethlon Medical, Inc. is a clinical-stage medical technology company focused on developing blood purification therapies designed to address life‑threatening diseases. The company operates within the medical device and biotechnology industries, with a particular emphasis on infectious diseases, oncology, and inflammatory conditions. Its core technology platform is intended to selectively remove harmful pathogens and disease‑causing agents from the bloodstream, rather than targeting them with pharmaceuticals.

The company’s primary product candidate is the Hemopurifier®, an extracorporeal blood filtration device designed to bind and remove circulating viruses, viral fragments, exosomes, and certain tumor-derived particles. Aethlon Medical serves hospital systems, critical care providers, and clinical research institutions, primarily in regulated healthcare markets. Founded in 1998, the company has evolved from early-stage research into a publicly traded, clinical-stage organization conducting human studies under regulatory oversight, while continuing to refine its proprietary filtration technology.

Business Operations

Aethlon Medical operates as a single-reportable-segment company focused on research, development, and clinical validation of its blood purification technology. Revenue generation to date has been limited and primarily consists of grant funding and limited research-related income, as the company has not yet received full regulatory approval for commercial sales. Its operations are centered on advancing clinical trials, regulatory submissions, and manufacturing readiness for its device platform.

The company’s core asset is the Hemopurifier®, which incorporates proprietary affinity resins designed to capture targeted particles from blood during dialysis-like procedures. Operations are primarily domestic, with clinical and regulatory activities conducted in collaboration with U.S. medical institutions, while certain manufacturing and component sourcing activities involve international suppliers. Aethlon Medical does not report material joint ventures or large operating subsidiaries; its activities are conducted directly through the parent company.

Strategic Position & Investments

Aethlon Medical’s strategy centers on positioning the Hemopurifier® as a novel adjunctive therapy for conditions where circulating pathogens or disease mediators contribute to severe outcomes. Growth initiatives focus on expanding clinical indications, including viral infections and oncology applications, and advancing the device through regulatory pathways such as FDA Emergency Use and Investigational Device Exemptions.

The company has made targeted investments in clinical studies, manufacturing scale‑up capabilities, and intellectual property protection related to its filtration technology. Rather than pursuing broad acquisitions, Aethlon Medical has emphasized internal development and selective clinical collaborations. Its emerging focus includes the role of exosomes and extracellular vesicles in cancer progression and viral persistence, which management views as a differentiating scientific opportunity. Data regarding the long-term commercial scalability of these initiatives remains inconclusive based on available public sources.

Geographic Footprint

Aethlon Medical is headquartered in North America, with its principal executive offices located in San Diego, California. The company’s operational footprint is primarily U.S.-based, reflecting its focus on FDA-regulated clinical development and domestic healthcare systems.

Internationally, the company has engaged in limited clinical and research activities through collaborations and regulatory engagements outside the United States, including prior studies conducted in Europe and other regions. These activities do not currently represent significant ongoing commercial operations but demonstrate the company’s intent to pursue global regulatory pathways if its technology achieves clinical and regulatory milestones.

Leadership & Governance

Aethlon Medical is led by executives with experience in medical devices, biotechnology commercialization, and public company governance. Leadership emphasizes a strategy focused on clinical validation, regulatory compliance, and disciplined capital management to advance its technology toward potential approval and adoption.

Key members of the leadership team include:

• James A. Joyce – Chief Executive Officer
• Jim Frakes – Chief Financial Officer
• Dr. Steven LaRosa – Chief Medical Officer
• Michael S. Garone – Vice President of Clinical Operations

The company is governed by a board of directors that includes individuals with backgrounds in healthcare, finance, and life sciences. Management has articulated a vision centered on establishing blood purification as a complementary therapeutic category in modern medicine, though the timing and scope of commercial realization remain subject to clinical and regulatory outcomes.